Screener
Supernus Pharmaceuticals SUPN Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Royalty, licensing, and other revenues | 29,309 | 7,836 |
| Total revenues | 207,705 | 149,824 |
| Costs and expenses | ||
| Cost of revenues(a) | 23,391 | 15,763 |
| Research and development | 39,438 | 26,927 |
| Selling, general and administrative | 125,173 | 89,944 |
| Amortization of intangible assets | 25,644 | 19,786 |
| Contingent consideration loss | 2,391 | 7,660 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's total cost of revenue?
- Supernus Pharmaceuticals (SUPN) reported total cost of revenue of $23.39M in Q1 2026.
- How has Supernus Pharmaceuticals's total cost of revenue changed year-over-year?
- Supernus Pharmaceuticals's total cost of revenue increased by 48.4% year-over-year, from $15.76M to $23.39M.
- What is the long-term trend for Supernus Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's total cost of revenue has grown at a -0.2% compound annual growth rate (CAGR), from $75.06M to $74.56M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Supernus Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude